SEARCH

SEARCH BY CITATION

References

  • 1
    Sandhu A, Alameel T, Dale CH, Levstik M, Chande N. The safety and efficacy of antitumor necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther 2012; 36: 15965.
  • 2
    Mohabbat AB, Sandborn WJ, Loftus EV Jr, Wiesner RH, Bruining DH. Anti-tumor necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther 2012; 36: 56974.
  • 3
    Lal S, Steinhart AH. Infliximab for ulcerative colitis following liver transplatation. Eur J Gastroenterol Hepatol 2007; 19: 27780.
  • 4
    El-Nachef N, Terdiman J, Mahdevan U. Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation. Am J Gastroenterol 2010; 105: 12101.
  • 5
    Indriolo A, Fagiuoli S, Pasulo L, et al. Infliximab in patients with ulcerative colitis and primary sclerosing cholangitis before and after liver transplantation. JCC 2012; 6(Suppl. 1): S117.